Ostial

About Ostial

Ostial Corporation, founded in 2008 by Fred Khosravi, operates as a private medical technology company from its headquarters in Campbell, California. The firm is focused on developing solutions for the clinical challenges associated with aorto-ostial interventions, which are procedures performed at the opening of an artery. Ostial is an Incept LLC portfolio company and has received financial backing from investors including Delos Capital and AMED Ventures.

The company’s flagship product is the FLASH™ Aorto-Ostial Angioplasty System, a dual-balloon catheter designed to address the difficulties of stenting in aorto-ostial locations. This system is engineered for use in both coronary and peripheral arteries. Its key feature is a dual-balloon mechanism: a non-compliant distal balloon anchors the system post-dilation, while a compliant proximal balloon allows the physician to position the catheter precisely and flare the stent for complete 360° coverage against the ostium wall. This design aims to optimize patient outcomes and simplify vessel reaccess for future interventions. The FLASH system is commercially available in the United States and, as of February 2023, was being used in 350 hospitals with 19,000 units sold.

Ostial's business model revolves around the sale of its proprietary FLASH system to hospitals and medical professionals. The company also emphasizes physician training to ensure the effective use of its specialized device. Significant milestones for the company include reaching 15,000 commercial units sold by May 2020 and closing a $7.5 million Series C funding round in February 2023. This funding was intended to accelerate the commercialization of the FLASH system by expanding the sales force and supporting further clinical research. In March 2025, Ostial announced its new identity as Verge Medical following the strategic acquisition of Wavella™ technology from Crossfire Medical, signaling an expansion into broader coronary and peripheral markets. The leadership team includes Fred Khosravi as Chairman of the Board and Mike Buck, who was appointed CEO in July 2024, bringing over 30 years of cardiovascular industry experience.